Episode 32: t(11;14) Multiple Myeloma and Role of Venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser

Blood Cancer Talks

A tartalmat a Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.

12M ago 58:50

MP3•Epizód kép

In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser.

Here are the shownotes:

1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma:

https://x.com/Rfonsi1/status/1206004966294294528?s=20

2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs:

https://pubmed.ncbi.nlm.nih.gov/28655925/

3. BELLINI trial (Ven-Bort-Dex vs Bort-Dex in all-comers):

https://pubmed.ncbi.nlm.nih.gov/33129376/

4. Efficacy of Dara-VCD by cytogenetic subgroups in AL Amyloidosis:

https://pubmed.ncbi.nlm.nih.gov/36779691/

5. CANOVA Trial (Ven-Dex vs Pom-Dex in t[11;14]):

https://www.clinical-lymphoma-myeloma-leukemia.com/issue/S2152-2650(23)X0011-1?pageStart=0

6. Phase 1/2 trial on Daratumumab-Venetoclax-Dex in Relapsed/Refractory Myeloma:

https://pubmed.ncbi.nlm.nih.gov/34388020/

7. Phase 1/2 trial on Venetoclax-Carfilzomib-Dex in relapsed/refractory myeloma:

https://pubmed.ncbi.nlm.nih.gov/34470049/

52 epizódok

#Fitness #Medicine #Rajshekhar Chakraborty and Ashwin Kishtagari #Ashwin Kishtagari #Rajshekhar Chakraborty #Hematology #Cancer #Podcasting Education #Edward Cliff